BChE-IN-14 (compound 19c) is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.011 μM for hBChE and 0.23 μM for eqBChE, exhibiting primary cell safety and good blood-brain barrier permeability. It can restore cognitive impairment in vivo and is useful in Alzheimer's disease research [1].

BChE-IN-14, at concentrations ranging from 0.0001 to 100 μM, effectively inhibits both equine serum BChE (eqBChE) and human BChE (hBChE), with half-maximal inhibitory concentrations (IC50) of 0.23 μM and 0.011 μM, respectively [1].

BChE-IN-14, administered orally at a dosage of 15 mg/kg from days 3-8 post Aβ 1-42 injection, enhances memory and cognitive functions in an Alzheimer's Disease (AD) mouse model [1]. This was observed in ICR mice injected with oligomerized Aβ 1-42 peptide [1], where BChE-IN-14 not only improved in vivo memory and cognition but also demonstrated quicker response times compared to donepezil.